# Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

> **NCT05663827** · PHASE3 · COMPLETED · sponsor: **Yi-Lun Wang** · enrollment: 6 (actual)

## Conditions studied

- Steroid Refractory GVHD

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT05663827
- **Lead sponsor:** Yi-Lun Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2022-11-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05663827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05663827, "Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05663827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*